Background and objective: New treatments for idiopathic pulmonary fibrosis (IPF) have improved survival; however, the complexity of care may be difficult for patients. The aim of this study was to assess the patient experience of modern IPF care. Methods: A qualitative study was undertaken for 100 people with IPF with a range of disease severity (forced vital capacity range: 46-106% predicted). Participants were asked about their experience of care using semi-structured interviews. Two investigators independently undertook analysis using the principles of grounded theory. Results: Participants reported dissatisfaction with information received about IPF, particularly at the time of diagnosis. Most were enthusiastic about the benefits of specialist IPF centres including regular monitoring, frequent contact with health professionals and access to clinical trials. However, the burden of travel to specialist centres and costs of treatment were significant. Many reported that side effects of anti-fibrotics caused them to titrate or pause therapy, sometimes without consulting their treating team. Co-morbid medical conditions had a negative impact on well-being and highlighted poor coordination of care. Participants perceived a responsibility for self-management that included exercise, diet, vaccination and treatment of chest infections; many felt this active role should receive more positive emphasis from health professionals. Conclusion: These data show opportunities to improve modern IPF care including accurate and timely provision of information, improving access to specialist care, more support for managing treatment side effects and better coordination of care for patients with co-morbid conditions. Future research should explore the impact of self-management strategies on IPF outcomes.
INTRODUCTION
New treatments have slowed disease progression and improved survival in idiopathic pulmonary fibrosis (IPF). 1, 2 Despite these advances, the modern IPF care pathway can be complex. Modern IPF care includes a multidisciplinary team (MDT) meeting to ensure diagnostic accuracy and determine therapeutic options 3 ; consideration of anti-fibrotic therapy for eligible patients; optimization of co-morbidities; nonpharmacological treatments such as oxygen therapy and pulmonary rehabilitation; and early referral for lung transplantation. 4 Whilst these treatments may improve outcomes, they could also give rise to unforeseen challenges for patients. It is possible that the MDT meeting process increases uncertainty for patients at a vulnerable time, particularly if the diagnosis is altered. Whilst anti-fibrotic therapy is advocated in guidelines, 5 current pharmacological approaches have relatively narrow indications; in Australia, prescription of antifibrotics is only possible when the diagnosis of IPF is confirmed by an MDT meeting and there is a mild-tomoderate impairment of lung function. 4 Patients may be disappointed if they are ineligible for pharmacological treatment, whilst those who are offered anti-fibrotic therapy may experience a range of side effects. Other treatment options such as lung transplantation, pulmonary rehabilitation, oxygen therapy, symptom management and clinical trial inclusion may not be offered consistently to all patients.
Whilst a number of studies have reported the experience of having IPF prior to the anti-fibrotic era, [6] [7] [8] 
SUMMARY AT A GLANCE
People with idiopathic pulmonary fibrosis (IPF) were dissatisfied with the information provided at diagnosis but valued specialist IPF care. Participants experienced a high burden of treatment side effects. Those with co-morbidities perceived that their care was not well coordinated. Participants felt that their active role in self-management of IPF was underappreciated by health professionals.
there are emerging data from small studies on the experience of pirfenidone, 9, 10 there are no studies that comprehensively document the patient experience of modern IPF care. We aimed to document this experience, in order to improve the IPF care pathway, enhance patient-centred care and improve outcomes.
METHODS
A qualitative study using semi-structured interviews was undertaken. Adults enrolled in the Australian IPF Registry 11 were invited to take part by letter. There were no exclusion criteria. Individual semi-structured interviews were conducted over the telephone by an independent researcher with a background in respiratory science (K.B.) using an interview schedule (Box 1). Questions covered experiences of diagnosis, treatment and living with IPF. Digital recordings were transcribed verbatim. At the time of the study, anti-fibrotic medications were not approved for use in Australia; however, many patients had current or past access via clinical trials, and some patients accessed anti-fibrotic therapy independently. Demographic data (age and respiratory function) were collected from the Australian IPF Registry with participant permission. The study was approved by the Alfred Hospital Ethics committee (project 67/16) and all participants gave verbal consent to participate in a telephone interview and consent was audio recorded.
Data analysis was conducted by two investigators (A.E.H. and K.B.) using the principles of grounded theory. 12 Transcripts were read line-by-line and fragmented into descriptive codes (open coding). Codes were then ordered hierarchically to form themes and subthemes. The final themes were agreed through discussion. Quotations were extracted to provide illustrative data and are presented in boxes. Data were coded using nVivo version 10 (QSR International, Melbourne, Australia). We selected a large sample size of 100 participants a priori, because we anticipated that there would be a wide range of patient experiences, and to ensure good representation across subgroups of interest, which were those whose diagnosis included an MDT meeting (group 1); participants currently using antifibrotic therapy (group 2); participants who had ceased using anti-fibrotic therapy (group 3); and participants who had not been offered anti-fibrotic therapy (group 4). Data analysis confirmed that saturation was achieved. 13 Consolidated criteria for reporting qualitative research (COREQ) guidelines were followed. 14 
RESULTS
A total of 424 invitations were sent, with the first 100 respondents (61 males) included. Five participants identified that their diagnostic pathway had included an MDT meeting (group 1) Forty-six participants were using anti-fibrotic therapy (group 2), 7 had ceased antifibrotic therapy (group 3), 39 had not been offered anti-fibrotic therapy (group 4) and eight could not report whether they had used anti-fibrotic therapy. Ages ranged from 57 to 90 years, forced vital capacity from 46 to 106% predicted (Median: 77%) and diffusing capacity for carbon monoxide 21 to 95% predicted (median: 54%). On average, the interviews took 28 min. Caregivers were present during five interviews and were welcome to contribute to the conversation, although most chose a predominantly supportive role with little direct contribution. Six major themes were identified (Box 2).
Desire for information and support
Experiences of diagnosis were diverse. Many participants described not receiving enough information at the time of diagnosis, which had been frustrating and distressing. Some felt as though information was withheld by their clinician, causing them to seek information elsewhere, sometimes with distressing consequences when the prognosis became apparent. Although some spoke of a protracted diagnostic pathway, others were happy with the process and relieved to finally know the cause of their symptoms. Many wanted information about what they should expect in the future and felt they had not received this (Box 3).
Almost all participants had turned to the internet for information. For some, this confirmed what they understood and empowered them to manage their condition, but others found information that was shocking and upsetting. A number of participants said that written information would be best for them, particularly at the time of diagnosis. Those who had met others with IPF, in seminars, peer support groups, online forums and pulmonary rehabilitation, were positive about this experience. Others expressed their desire for such opportunities.
The benefits of specialist IPF care
Referral to IPF specialist centres enabled access to clinical trials and frequent monitoring. This had a positive impact on the experience of care, with IPF specialist nurses being especially valued. Participants were keen to contribute to research and teaching so that the experience of IPF could be improved in the future. This included involvement in clinical trials, participating in medical student exams, donating their bodies after death or filling out questionnaires. Other reasons for clinical trial participation included personal health gains and access to pharmacotherapy. However, some felt that there was inadequate feedback from their involvement in trials (Box 4).
Diverse experiences of treatments
Many participants on anti-fibrotic therapy had found the side effects burdensome; however, most were prepared to endure this for the potential gain in health. Many described marked weight loss since the beginning of anti-fibrotic therapy. Individualized management of side effects allowed most to continue taking anti-fibrotics, with strategies including reducing the dose, increasing sun protection, ensuring tablets were taken with food or taking an anti-diarrhoeal. Some reported using strategies that they had not discussed with their doctor (e.g. pausing treatment). There was a strong desire for medications with fewer side effects and more specific advice on managing side effects of existing therapies (Box 5). Participants who had been involved in pulmonary rehabilitation described physical, psychological and social benefits. Exercise training was considered an healthcare environment 'I immediately dived into the internet and got on to Dr Google…. I was able to get quite a lot of information relatively quickly which is a classic example I think of the old story that if you're informed and aware and understand a circumstance or a situation then you're in much better shape of handling it and dealing with it'. P064, group 2 '…again on the internet it recommends the rehabilitation quite strongly whereas the doctor spoke with the nurse at the hospital R that do the lung rehab sessions and they felt that I was unlikely to get any benefit from it. So I haven't followed it up'. P042, group 2 'In those early months I would dearly have loved somebody to talk to about it. Someone who was in very early stages, which I am….'. P043, groups 1 and 2 integral component, but education sessions were also highly valued, despite limited content that was specific to IPF. Several participants felt that programmes were too short and that maintenance programmes in the community did not meet their needs, as exercise instructors had little experience of IPF. Oxygen therapy had allowed some people to be independent and some reported that it helped with their cough. Others felt that it did not help during exercise and some used it only during recovery. Many reported the practical burden of using oxygen, including dragging a heavy tank and managing the tubing. Some found that portable concentrators were easier to use. Several felt they had received insufficient information and practical support for how to use their oxygen and as a result they did not use it very much. The lack of treatment options was a frustration and a significant number of participants also used complementary and alternative therapies. These included massage, cupping, peppermint oil, cough tonics, cough lozenges, nasal spray, sucking ice cubes, nutritional supplements, Echinacea, handheld fans and salt pipes. A small number of participants talked about lung transplantation, with several reporting that they were too old and ineligible. Only one participant, with end-stage disease, mentioned palliative care.
Influence of co-morbidities on well-being
Many participants spoke of managing IPF alongside coexisting medical conditions including heart disease, 'It may not help me, but in years to come I really hope it helps other people as to diagnosis as well as therapy, receiving therapy, because a lot of it is trial and error I think'. P047, group 2 'I was happy to go on any trial at all if there was a slightest chance that anything could help me'. P039, no group 'I mean I'm feeling that it's not improving but you don't, with these clinical trials you don't get told anything. And that's frustrating, you know, you'd like to know, well hang on is it getting worse is it getting better….'. P035, group 2 vascular disease, renal problems and arthritis. Sometimes coexisting health problems made it difficult to distinguish between disease symptoms and drug side effects. Other health issues had limited their use of IPF therapies, which made them feel as though their IPF care was put on hold. Some participants perceived that each of their specialists worked in isolation, which had increased the burden of medication side effects. Others just accepted that care could not be coordinated and that this meant they could not access some treatments, such as attending rehabilitation classes that conflicted with other appointments (Box 6).
Burdens of IPF care
A large number of participants, especially from regional areas, described long, tiring and expensive travel that sometimes resulted in only brief consultations with their healthcare professionals. Some had ceased attending appointments due to the distance they had to travel. Several participants had not been offered pulmonary rehabilitation as it was not available locally. Surprisingly, despite universal healthcare coverage in Australia, a number of participants described the financial burden of IPF including costs associated with antifibrotics, oxygen, rehabilitation, home modifications and attending respiratory seminars. Some participants had experienced a loss of income from paid work (Box 7).
The importance of active self-management and a positive attitude
Participants spoke of the importance of actively managing their health. They described a sense of personal responsibility for optimizing those aspects of healthy living that were within their control. A good diet, regular exercise and vaccinations were seen as critical to staying well for as long as possible. A number of participants described self-administering antibiotics and steroids when they felt it was needed, either with or without the knowledge of their physician. Many took a similar approach to anti-fibrotic treatment, describing titrating their medication to manage side effects and ensure they could engage in valued activities (Box 8).
Although participants understood that they had a poor prognosis, many wanted their health professionals to present a more positive outlook and more opportunities for self-management. Having options for treatment (e.g. choosing to undertake rehabilitation, recognizing and managing exacerbations and having vaccinations) gave hope and a greater sense of control.
DISCUSSION
This study has documented the experience of modern IPF care in a large group of patients in Australia. would … catch a train … at 4 o'clock in the morning so that I could be there in time…and then I wouldn't get home till 10 o'clock at night, you know? And all for, you know, probably 20 minutes for lung function and 15 minutes or so for the doctor'. P057, group 4 '…nobody ever mentioned anything to me about any pulmonary rehab. I didn't even know such a thing existed and probably because I wasn't staying in (the city) nobody probably mentioned it for that reason'. P043, groups 1 and 2 Financial burden 'I've got the oxygen. I used to be on it when I first got it, I used to hire it. I was on it in hospital, two units I think it was and then came home and I hired one. I was on that 24 hours a day and then I thought this is too expensive. The specialist said I'll be on it forever so I thought oh well I'll just buy one, so $4700 later'. P017, group 2 'Yes, I had gym rehabilitation and I really enjoyed it, but I am a pensioner and I don't have extra money'. P086, group 2 '…with the lung and my heart and my back I had to stop working, so I haven't been working since the year 2000. But, and that's a bad experience, I live on the pension it's not much… I can't do much at all'. P074, group 4
Qualitative interviews revealed dissatisfaction with information received, particularly at the time of diagnosis. Participants were enthusiastic about the benefits of specialist IPF care, including regular monitoring and access to clinical trials. However, the burden of travel to specialist centres and costs of treatment were significant. Many reported unwelcome side effects of antifibrotics that caused them to pause or titrate their dose, with or without their physician's knowledge. Comorbid medical conditions had a significant impact on well-being and highlighted the need for better coordination of care. Importantly, participants saw themselves as active participants in their care, with a responsibility for self-management that included exercise, diet, vaccination and treatment of chest infections. Many felt strongly that this active role should receive more emphasis from healthcare professionals. Unlike previous studies, 8, 9 participants reported a diagnostic course that was not universally protracted. It is possible that the growth of specialist IPF centres in Australia and availability of new therapies have raised awareness of IPF as a differential diagnosis. Although many participants were managed at specialist IPF centres, which are available in major cities across Australia, few had any awareness of the role of the MDT meeting in diagnosis, and as a result they did not perceive that this delayed the process. However, the manner in which the diagnosis was delivered was poorly received. Many participants felt that clinicians should be more positive, providing information about the importance of active self-care including exercise, nutrition and management of chest infections. Selfmanagement is considered an integral component of care for other lung diseases, 15 the patient perspectives documented in this study suggest that they perceived a similar role in modern IPF care. This is the first time that the theme of self-management has emerged in a study of the experience of living with IPF. It is possible that this represents a change in perception of IPF in the anti-fibrotic era, such that some patients now view it as a treatable condition which can be controlled with appropriate pharmacological treatment and self-care. The potential for people with IPF to play an active role in their care, and the impact of this on IPF outcomes, is worthy of further investigation.
Many participants in this study expressed a desire to know what the future would hold for them. The importance of understanding prognosis, on an individual level rather than a group average, also emerged in our previous qualitative research 16 and that of others. 17 However, it contrasts with another recent qualitative study where many were ambivalent about receiving information about disease progression. 18 Other authors have reported that carers were more likely than patients to seek frank information about prognosis, especially if the patient was deteriorating. 19 Predicting disease behaviour in an individual patient is challenging as the clinical course is highly variable. 20 However, the themes emerging from this study suggest that for many patients, a conversation with their clinician regarding what the future might hold would be highly valued, even if certainty cannot be provided.
Participants reported anti-fibrotic side effects that were common and distressing. Some had paused or titrated their anti-fibrotic medications to control side effects, sometimes without their physician's knowledge. This reflects a determination to continue on treatment, in the hope that the benefits would outweigh the discomforts. Previous research reported that those who experienced side effects with pirfenidone had lower satisfaction with their care and were less likely to perceive treatment as effective. 10 However, very few participants had elected to discontinue anti-fibrotic therapy altogether, similar to previous research in the United Kingdom and Austria. 9 Many expressed a desire for more specific guidance on managing side effects, despite the fact that most had access to specialist IPF nurses. Participants also confirmed that treatments with fewer side effects are a high priority.
The impact of co-morbidities on the experience of IPF care was highlighted in this study. As well as limiting the opportunity to engage in IPF-specific treatments, participants identified poor coordination of care across services as affecting their well-being. Comorbidities are an independent predictor of depression in people with lung fibrosis. 21 The impact of comorbidities on IPF outcomes is well known [22] [23] [24] [25] and active treatment is recommended. 5 The patient perspectives expressed in this study suggest that provision of such care is not sufficient to alleviate disease Box 8: The importance of active selfmanagement and a positive attitude Personal responsibility for a healthy lifestyle 'I know people go downhill pretty quickly once they start going downhill. I'm aware of that so I'm doing my best to keep myself fit and active, and healthy as I possibly can'. P093, group 3 'I do an exercise routine three to four times a week and try and stay as healthy as I can. My wife ensures that I have a very good diet. She's very diet conscious and everything. So that's good'. P096, group 4 Self-management "I had an overseas trip 2 years ago for my 80th birthday… I did put myself on the maximum steroids, I was told to take them with me so I just stayed on steroids for the whole time I was away, and when I came home came down off them and I was well. Very well all the time I was away as far as my lungs were concerned'. P066, group 4 'Like I said the care, the care really is down to yourself, exercise, try and look after yourself and just do the best you can'. P56, no group Health professionals providing positive messages about self-care 'I would like to see a more positive attitude. I can see that you can't be honest and have a positive attitude, but surely you can present the facts in a way that gives the person something that they feel they're having some control over, particularly as the tablets they're asking you take are dreadful'. P041, group 2 burden; well-coordinated care is required. Specialist IPF nurses, with their detailed knowledge of both individual patient needs and local health services, may be well positioned to take an active role in care coordination. Experiences of other IPF treatments varied and were influenced by outcomes, burden and cost. Most had positive experiences of pulmonary rehabilitation, although some were dissatisfied with the availability or cost of community-based maintenance programmes. Several participants had not been offered pulmonary rehabilitation, particularly in regional areas. Poor access to pulmonary rehabilitation is well documented, [26] [27] [28] a recent position statement 29 calls for new models to enhance access, such as home-based rehabilitation or tele-rehabilitation. Similarly, telehealth could prove useful to decrease the burden of travel to specialist IPF appointments. Use of alternative therapies was common, similar to a previous study from the United States. 7 The impact of such therapies on outcomes and interactions with conventional treatments is unknown. Palliative care was mentioned only once, despite consistent documentation of unmet symptom needs 30 and evidence that palliative care is feasible and acceptable in IPF. 31 We could not determine whether this reflected reluctance to discuss the topic, or lack of referral by health professionals such that patients did not have experience with palliative care. Previous research found that people with IPF were reluctant to engage with palliative care and had poor understanding of its goals. 32 Education of both patients and health professionals regarding the potential benefits of palliative care in IPF is required.
A strength of this study is that it provides patient perspectives on important aspects of IPF services, including access to specialist nurses, written information at the time of diagnosis, assistance with managing side effects and improved coordination of care. A limitation is that our results, like all qualitative studies, are not directly generalizable to other settings, and findings may have been quite different in environments without universal access to health care or different geography. Our findings should be considered hypothesisgenerating in other settings. Another limitation is that care delivered across Australia may be variable and patients may have a broad range of experiences, not all of which were captured in our study. We chose to conduct interviews over the telephone as this allowed inclusion of participants across a wide geographic area; however, it is possible that this limited the information obtained. We did not seek to include informal carers, so the perspectives of this important group are not represented. At the time of recruitment, anti-fibrotics were not approved for use in Australia, although many patients had access through clinical trials; this may also affect the generalizability of results. Recruiting participants from the Australian IPF registry gave a wellcharacterized group, however it is possible that they are not representative of those outside the registry.
In conclusion, people with IPF wanted more information about their condition and thought that clinicians should be more positive about the active role that patients could take in self-care. Side effects of antifibrotics were burdensome; self-titration and pausing of therapy were common. Although specialist IPF services are highly valued, patients with co-morbidities identified that improved coordination of care with other services is required. Further research should explore the nature and impact of self-management strategies on IPF outcomes.
